Literature DB >> 17444862

Resistance rate to antibiotics of Helicobacter pylori isolates in eastern Taiwan.

Chi-Tan Hu1, Chao-Chuan Wu, Chih-Yung Lin, Chuan-Chu Cheng, Siou-Cing Su, Yi-Hsiung Tseng, Nien-Tsung Lin.   

Abstract

BACKGROUND AND AIM: Prevalence of Helicobacter pylori (H. pylori) strains resistant to metronidazole, clarithromycin and amoxicillin is increasing worldwide. The aim of this study was to determine the antibiotic susceptibility patterns in H. pylori strains isolated from eastern Taiwan.
METHODS: One strain each of H. pylori was isolated from 133 symptomatic patients and subjected to determination of the minimal inhibitory concentration (MIC) by the Epsilometer test (E-test) for four antibiotics commonly used in the treatment of H. pylori infections.
RESULTS: None of the strains were resistant to tetracycline. Resistance to metronidazole (8 microg/mL), clarithromycin (1 microg/mL) and amoxicillin (8 microg/mL) was found in 51.9%, 13.5% and 36.1% of the isolates, respectively. Metronidazole-resistant strains were isolated more frequently from women (49/78; 62.8%) than from men (20/55; 36.4%). Resistance to at least two antimicrobial agents was detected in 33.8% of the isolates. There was a high rate of resistance to both metronidazole and amoxicillin (18.1%).
CONCLUSIONS: Clarithromycin and tetracycline may provide useful components of treatment regimens in eastern Taiwan. In addition, pretreatment microbial susceptibility testing rather than empiric therapy is highly recommended for eradication of H. pylori infection.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17444862     DOI: 10.1111/j.1440-1746.2006.04743.x

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  12 in total

1.  Clarithromycin-Based Triple Therapy is Still Useful as an Initial Treatment for Helicobacter pylori Infection in the Dominican Republic.

Authors:  Muhammad Miftahussurur; Modesto Cruz; Phawinee Subsomwong; José A Jiménez Abreu; Celso Hosking; Hiroyuki Nagashima; Junko Akada; Yoshio Yamaoka
Journal:  Am J Trop Med Hyg       Date:  2017-02-13       Impact factor: 2.345

2.  Who's Winning the War? Molecular Mechanisms of Antibiotic Resistance in Helicobacter pylori.

Authors:  Kathleen R Jones; Jeong-Heon Cha; D Scott Merrell
Journal:  Curr Drug ther       Date:  2008-09-01

3.  Integrative computational protocol for the discovery of inhibitors of the Helicobacter pylori nickel response regulator (NikR).

Authors:  Aldo Segura-Cabrera; Xianwu Guo; Arturo Rojo-Domínguez; Mario A Rodríguez-Pérez
Journal:  J Mol Model       Date:  2011-03-01       Impact factor: 1.810

4.  Contribution of specific amino acid changes in penicillin binding protein 1 to amoxicillin resistance in clinical Helicobacter pylori isolates.

Authors:  Nadia N Qureshi; Dimitrios Morikis; Neal L Schiller
Journal:  Antimicrob Agents Chemother       Date:  2010-10-18       Impact factor: 5.191

5.  Genome, integration, and transduction of a novel temperate phage of Helicobacter pylori.

Authors:  Cheng-Hung Luo; Pei-Yu Chiou; Chiou-Ying Yang; Nien-Tsung Lin
Journal:  J Virol       Date:  2012-06-13       Impact factor: 5.103

6.  Helicobacter pylori-pulsed dendritic cells induce H. pylori-specific immunity in mice.

Authors:  Min Zhang; Bradford E Berndt; Kathryn A Eaton; Sivaprakash Rathinavelu; Anna Pierzchala; John Y Kao
Journal:  Helicobacter       Date:  2008-06       Impact factor: 5.753

7.  Five-year sequential changes in secondary antibiotic resistance of Helicobacter pylori in Taiwan.

Authors:  I-Ting Wu; Seng-Kee Chuah; Chen-Hsiang Lee; Chih-Ming Liang; Lung-Sheng Lu; Yuan-Hung Kuo; Yi-Hao Yen; Ming-Luen Hu; Yeh-Pin Chou; Shih-Cheng Yang; Chung-Mou Kuo; Chung-Huang Kuo; Chun-Chih Chien; Yu-Shao Chiang; Shue-Shian Chiou; Tsung-Hui Hu; Wei-Chen Tai
Journal:  World J Gastroenterol       Date:  2015-10-07       Impact factor: 5.742

8.  Seven-Day Nonbismuth Containing Quadruple Therapy Could Achieve a Grade "A" Success Rate for First-Line Helicobacter pylori Eradication.

Authors:  Wei-Chen Tai; Chih-Ming Liang; Chen-Hsiang Lee; Chien-Hua Chiu; Ming-Luen Hu; Lung-Sheng Lu; Yuan-Hung Kuo; Chung-Mou Kuo; Yi-Hao Yen; Chung-Huang Kuo; Shue-Shian Chiou; Keng-Liang Wu; Yi-Chun Chiu; Tsung-Hui Hu; Seng-Kee Chuah
Journal:  Biomed Res Int       Date:  2015-05-19       Impact factor: 3.411

9.  Adding diclofenac to Helicobacter pylori eradication regimen.

Authors:  Mohammad Hasan Emami; Akbar Arjmandpour; Hamed Daghaghzadeh; Hojatollah Rahimi; Ali Toghiani; Peyman Adibi
Journal:  Adv Biomed Res       Date:  2015-07-27

10.  Levofloxacin-amoxicillin/clavulanate-rabeprazole versus a standard seven-day triple therapy for eradication of Helicobacter pylori infection.

Authors:  Ming-Cheh Chen; Wei-Yi Lei; Jen-Shung Lin; Chih-Hsun Yi; Deng-Chyang Wu; Chi-Tan Hu
Journal:  Biomed Res Int       Date:  2014-06-05       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.